Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.55 |
| ▸ | HTR3A | P46098 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.55 |
| ▸ | KHK | P50053 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GPR4 | P46093 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7920290 | 0.88 | PARP15 (0.50) | TDP1 | |
| SCHEMBL6223467 | 0.84 | TDP1 (0.48) | TDP1SLC6A2SLC6A4ITGB3ITGA2B | |
| SCHEMBL12718779 | 0.83 | ITGB3 (0.51) | TDP1SLC6A4ITGB3ITGA2B | |
| SCHEMBL82372 | 0.81 | TDP1 (0.73) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL14863368 | 0.78 | TDP1 (0.68) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL3244911 | 0.78 | SLC6A2 (0.77) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL2460394 | 0.78 | TDP1 (0.68) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL3251238 | 0.78 | TDP1 (0.68) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL1475391 | 0.78 | TDP1 (0.68) | TDP1SLC6A2SLC6A4HTR3AKCNH2 | |
| SCHEMBL796789 | 0.78 | SLC6A2 (0.68) | TDP1SLC6A2SLC6A4HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1266896-B1 | Linear or cyclic ureas, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-01-17 | — | — | EP | disclosed |
| US-6908922-B2 | Anticholesterol agents; cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-06-21 | — | — | US | disclosed |
| US-6903103-B2 | Linear cyclic ureas | LES LABORATORIES SERVIER (FR) | 2005-06-07 | — | — | US | disclosed |
| EP-1113014-B1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-04-27 | — | — | EP | disclosed |
| US-6780868-B2 | TREATMENT OF MYOCARDIAL OR PERIPHERAL ISCHAEMIA, CARDIAC INSUFFICIENCY OR PULMONARY ARTERIAL HYPERTENSION | LES LABORATOIRES SERVIER (FR) | 2004-08-24 | — | — | US | disclosed |
| US-20030229100-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-11 | — | — | US | disclosed |
| US-20030225105-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-12-04 | — | — | US | disclosed |
| US-20030191132-A1 | New linear cyclic ureas | PEGLION JEAN-LOUIS (FR) | 2003-10-09 | — | — | US | disclosed |
| US-6566364-B2 | Isomers, hydrates, solvates and addition salts in treatment of endothelial dysfunction disease such as atherosclerosis, dyslipidaemia; antidiabetic agents; heart transplantation; inhibition of nitrogen monoxide synthase and oxidative stress | LES LABORATOIRES SERVIER (FR) | 2003-05-20 | — | — | US | disclosed |
| EP-1266896-A1 | Linear ou cyclic ureas, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-20010009911-A1 | New linear or cyclic ureas | LES LABORATOIRES SERVIER (FR) | 2001-07-26 | — | — | US | disclosed |
| EP-1113014-A1 | Linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009911-A1 | New linear or cyclic ureas | GUCY1B1, UACA, LIPG | TDP1 1887/4885SLC6A2 2924/4885SLC6A4 3681/4885 |
| US-20030191132-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | TDP1 1962/4885SLC6A2 3299/4885SLC6A4 4053/4885 |
| US-20030229100-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | TDP1 1962/4885SLC6A2 3299/4885SLC6A4 4053/4885 |
| US-20030225105-A1 | New linear cyclic ureas | GUCY1B1, UACA, GUCY1A1 | TDP1 1962/4885SLC6A2 3299/4885SLC6A4 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.